The bullish options tilt that defined Oruka Therapeutics just days ago has flipped sharply. A put-call ratio that sat below 0.41 for most of the past week surged to 0.87 on September 24 — a z-score of 3.47 standard deviations above the 20-day mean. That is the clearest sign yet that sentiment has turned.
The PCR move deserves attention on its own terms. The 20-day average PCR was 0.48. Wednesday's reading nearly doubled it in a single session. A z-score above 3.0 is statistically extreme. The backdrop: ORKA fell 4.9% on September 24 alone and is down 16.5% over the past month. Options traders are reaching for protection at a rate not seen since August.
The contrast with the prior article is stark. Two days ago, options were leaning bullish while shorts rebuilt quietly. That split has now closed. Both camps are pointing the same direction.
SI stood at 18.2% of free float as of September 23, up 10.7% week-on-week and 16.6% over the past month. That is a continued acceleration from the 17.9% level reported just one session earlier. The ORTEX short score has climbed to 71.1 — its highest reading in the current window, up from 64.4 on September 18.
Cost to borrow has also moved. It jumped 193% over the week to 0.66% — still low in absolute terms, but the pace of the move is notable. Availability sits at 211%, confirming the lending market is not the constraint. Shorts are choosing to add, not being forced by borrow scarcity.
One counterpoint: analysts are not moving. Wedbush reiterated Outperform with a $165 target on September 24. HC Wainwright reiterated Buy at $120 the same day. The mean analyst price target sits at $153.75 — nearly 80% above the current price of $85.49. Guggenheim's target is $200.
That gap between analyst conviction and market behavior is widening. The stock has dropped 16.5% in a month while no firm has cut its rating or target.
The most recent institutional data shows FMR added 1.6 million shares and BlackRock added 1.5 million, both as of August 31. Capital Research initiated a position of 3.4 million shares in the same period. T. Rowe Price added 1.2 million shares as of September 1. These are large, recent builds — but they predate the September selloff.
Watch whether the options skew holds or reverses into earnings. A PCR at this z-score that quickly normalises often signals a flush. One that persists typically reflects a more durable shift in positioning.
See the live data behind this article on ORTEX.
Open ORKA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
